Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. 

The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. 

The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. 

Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .

This morning we announced that our lead clinical compound, LB-100, can kill cancer cells through hyper-stimulation of cell proliferation signals in pre-clinical models, according to a report published in Cold Spring Harbor Laboratory's bioRxiv titled, “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” Click the graphic to read comments from the report's co-author and Lixte's CEO, John Kovach, MD, on how the data suggests that paradoxical activation of oncogenic signaling can result in tumor suppressive resistance. #LB100 #cancer #hyperstimulation #Lixte #BixRxiv 

https://lnkd.in/gNnwzmns

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	107.77K -	122.53K 13.70%	159.08K 29.82%	159.59K 0.33%	312.03K 95.52%	195.21K 37.44%	143.55K 26.46%	190.29K 32.56%	225.97K 18.75%	229.76K 1.68%
accumulated other comprehensive income loss
cash and cash equivalents	475.02K -	44.41K 90.65%	25.28K 43.07%	199.93K 690.83%	1.31M 553.11%	4.27M 227.25%	2.60M 39.18%	5.07M 95.06%	4.82M 4.84%	5.35M 10.98%	4.20M 21.48%
cash and short term investments	481.15K -	258.11K 46.36%	129.38K 49.88%	199.93K 54.53%	1.31M 553.11%	4.27M 227.25%	2.60M 39.18%	5.07M 95.06%	4.82M 4.84%	5.35M 10.98%	4.20M 21.48%
common stock	4.16K -	4.55K 9.38%	4.79K 5.26%	4.79K 0%	5.80K 21.20%	6.70K 15.55%	6.70K 0%	1.24K 81.50%	1.37K 10.81%	1.66K 21.11%	3.50M 210,236.54%
deferred revenue	47.28K -	58.19K 23.06%	124.57K 114.08%	59.06K 52.59%	60.99K 3.27%	15.70K 74.25%	94.35K 500.80%	15.77K 83.29%	76.96K 388.18%	165.02K 114.42%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory			60.92K -
long term debt
long term investments
net debt	-475.02K -	-44.41K 90.65%	-25.28K 43.07%	-199.93K 690.83%	-1.31M 553.11%	-4.27M 227.25%	-2.60M 39.18%	-5.07M 95.06%	-4.82M 4.84%	-5.35M 10.98%	-4.20M 21.48%
net receivables			200K -				14.37K -
other assets
other current assets	33.88K -	231.18K 582.34%	207.68K 10.17%	183.49K 11.65%	62.32K 66.04%	61.43K 1.42%	58.80K 4.28%	15K 74.49%	10.25K 31.67%	10.38K 1.28%	105.13K 912.83%
other current liabilities	47.28K -	58.19K 23.06%	124.57K 114.08%	59.06K 52.59%	60.99K 3.27%	210.91K 245.82%	237.90K 12.79%	10.47K 95.60%	302.93K 2,794.11%	394.79K 30.32%	313.86K 20.50%
other liabilities										-394.79K -
other non current assets						2.29K -
other non current liabilities										394.79K -
othertotal stockholders equity	13.18M -	15.98M 21.20%	17.13M 7.20%	17.42M 1.68%	20.00M 14.86%	25.27M 26.31%	26.02M 2.96%	31.86M 22.48%	38.37M 20.42%	45.06M 17.43%	48.98M 8.70%
preferred stock			1.75M -	3.50M 100%	3.50M 0%	3.50M 0%	3.50M 0%	3.50M 0%	3.50M 0%	3.50M 0%
property plant equipment net
retained earnings	-12.95M -	-15.72M 21.36%	-18.57M 18.16%	-20.71M 11.49%	-22.52M 8.73%	-24.65M 9.47%	-27.09M 9.90%	-30.35M 12.05%	-37.08M 22.17%	-43.39M 17.02%	-48.48M 11.72%
short term debt	119.43K -	34.53K 71.09%	-122.57K 454.94%	-59.06K 51.82%	-60.99K 3.27%	-210.91K 245.82%	-237.90K 12.79%		-302.93K -	-394.79K 30.32%
short term investments	6.13K -	213.70K 3,383.28%	104.09K 51.29%
tax assets
tax payables
total assets	558.04K -	539.30K 3.36%	597.98K 10.88%	433.41K 27.52%	1.37M 215.65%	4.34M 217.00%	2.67M 38.39%	5.23M 95.67%	5.09M 2.59%	5.56M 9.16%	4.31M 22.51%
total current assets	558.04K -	539.30K 3.36%	597.98K 10.88%	433.41K 27.52%	1.37M 215.65%	4.33M 216.83%	2.67M 38.35%	5.23M 95.67%	5.09M 2.59%	5.56M 9.16%	4.31M 22.51%
total current liabilities	321.77K -	273.44K 15.02%	285.64K 4.46%	218.65K 23.45%	373.02K 70.60%	210.91K 43.46%	237.90K 12.79%	216.52K 8.98%	302.93K 39.90%	394.79K 30.32%	313.86K 20.50%
total debt
total investments	6.13K -	213.70K 3,383.28%	104.09K 51.29%
total liabilities	321.77K -	273.44K 15.02%	285.64K 4.46%	218.65K 23.45%	373.02K 70.60%	210.91K 43.46%	237.90K 12.79%	216.52K 8.98%	302.93K 39.90%	394.79K 30.32%	313.86K 20.50%
total liabilities and stockholders equity	558.04K -	539.30K 3.36%	597.98K 10.88%	433.41K 27.52%	1.37M 215.65%	4.34M 217.00%	2.67M 38.39%	5.23M 95.67%	5.09M 2.59%	5.56M 9.16%	4.31M 22.51%
total non current assets						2.29K -
total non current liabilities										394.79K -
total stockholders equity	236.27K -	265.86K 12.53%	312.33K 17.48%	214.76K 31.24%	995.04K 363.33%	4.13M 314.64%	2.43M 41.00%	5.01M 105.90%	4.79M 4.42%	5.17M 7.83%	3.99M 22.66%

NASDAQ:LIXT

Lixte Biotechnology Holdings, Inc.

Last Close

2.31

26/07 20:00

Market Cap

5.08M

Beta: −0.30

Volume Today

9.06K

Avg: 443.13K

PE Ratio

−0.76

PFCF: −1.01

Preview